Yuanbao Is a China Discount That Runs on Free Cash Flow

The market has spent the past year treating Yuanbao (NASDAQ: YB) like a business in trouble. Since last September the shares are down roughly 46%, and at about $13.40 they sit near their 52-week low, below both their 50- and 200-day averages. Then the March quarter landed: revenue up 35.6% to US$205.2 million, GAAP earnings of $1.26 per ADS, and a board that approved a $1.26-a-share annual dividend plus a $15 million buyback. The selloff matters less than the fact that expectations have already reset while the numbers have not broken.

A China discount, not a broken business

Yuanbao is China's largest independent online insurance distributor in personal life and accident-and-health coverage by first-year premiums, according to Frost & Sullivan — a broker that routes other insurers' products to more than ten million consumers through a technology platform. It owns insurance brokerage and agency licenses it collected in 2020 and 2021. There is nothing exotic about the model: it earns commissions on products underwritten by insurance carriers, which is why its gross margin runs in the mid-90s — a distributor does not carry the claims risk or the capital of the insurers whose policies it sells.

In the quarter it grew revenue to RMB 1.315 billion (US$205.2 million), up 35.6% from RMB 970 million a year earlier, while net income rose 31.4% to RMB 387.6 million (US$56.2 million). This was not a single lucky print. Revenue grew 33.6% in the third quarter and 34.5% in the fourth before Q1's 35.6% — three straight quarters of mid-30s growth. Chief executive Rui Fang described the industry pivoting from "scale expansion" to "high-quality development"; the trends, in plain numbers, simply kept accelerating.

The cash-flow bridge

Here is where the cheapness stops being a joke and becomes a bridge. The company's trailing free cash flow is about $211 million, up roughly 28% year over year, against a market capitalization of about $619 million. That is roughly three times free cash flow — a free-cash-flow yield near 34% — on a stock also carrying a trailing price-to-earnings ratio near two and a price-to-sales ratio under one.

The standard objection to a dirt-cheap China name is that the accounting is not real. That objection dies on the cash-flow statement. Operating cash flow over the same trailing window was about $214 million, and capital spending was trivial at under $3 million — so free cash flow essentially equals operating cash flow. The profits are cash-backed, not a pile of receivables. A commission broker does not need to reinvest in heavy assets, and it does not: nearly every dollar of earnings shows up as cash.

The dividend belongs in the same frame. A roughly 9% yield costs about $57 million a year, and the $15 million buyback pushes total cash returned to investors to around $70 million — against $211 million of free cash flow. The payout is covered about three times over. Sustainability is not the first question anyone should be asking here; the fear that choked the price is.

What would break it

Name the risk plainly: this is a China ADR, and that label carries real weight. Country and regulatory risk, the chance that regulators tighten how insurance is distributed in China, and the durability of commission rates in a competitive market are all live concerns. It is telling that the aggregate analyst signal still labels the stock a Buy even after the drawdown — a sign the derating has been about sentiment toward the name, not about the operating path. The market is still pricing the old risk profile while the operating setup has been getting cleaner underneath.

The measure that decides this thesis is free cash flow. The multiple only survives if the cash machine stays on: if revenue growth stalls toward the high teens or cash conversion deteriorates, if commissions compress or a regulatory change rewrites the model, then three times free cash flow stops being cheap and starts being a falling knife. I can be wrong again — a China policy shift or a step-down in cash generation would break the case. But as it stands, the setup is a company compounding mid-30s revenue growth that the market has already dismissed, priced at roughly three times the cash it generates and returning most of it to shareholders. That is an expectations reset, not a story that needs rescuing.